Here, we reported a case with concomitant ALK rare double-fusion, namely PLEKHA7-ALK and INPP5D-ALK in a patient diagnosed with lung adenocarcinoma who showed favorable response to alectinib following chemotherapy failure. This evidence concerns the gene PLEKHA7 and lung adenocarcinoma.